ESOMEPRAZOLE MAGNESIUM Drug Patent Profile

Which patents cover Esomeprazole Magnesium, and what generic alternatives are available?

Esomeprazole Magnesium is a drug marketed by Alkem Labs Ltd, Amneal Pharms Ny, Aurobindo Pharma Ltd, Cipla, Cisen, Cspc Ouyi, Dr Reddys, Ethypharm, Glenmark Speclt, Granules, Graviti Pharms, Guangzhou Novaken, Hec Pharm, Hetero Labs Ltd Iii, Indchemie Health, Lannett Co Inc, Macleods Pharms Ltd, Mylan, Prinston Inc, Sun Pharm, Torrent, Zhejiang Yongtai, Zydus Pharms, Aurobindo Pharma, Guardian Drug, Marksans Pharma, Perrigo R And D, Pharmobedient, P And L, and Dexcel. and is included in fifty NDAs. There are two patents protecting this drug.

This drug has four patent family members in three countries.

The generic ingredient in ESOMEPRAZOLE MAGNESIUM is esomeprazole magnesium. There are seventy-four drug master file entries for this compound. One hundred and ten suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Esomeprazole Magnesium

A generic version of ESOMEPRAZOLE MAGNESIUM was approved as esomeprazole magnesium by MYLAN on August 2^nd, 2015.

Summary for ESOMEPRAZOLE MAGNESIUM

International Patents:	4
US Patents:	2
Applicants:	30
NDAs:	50
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ESOMEPRAZOLE MAGNESIUM

Paragraph IV (Patent) Challenges for ESOMEPRAZOLE MAGNESIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	2.5 mg and 5 mg	021957	1	2018-09-24
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	10 mg	022101	1	2018-07-06
NEXIUM 24HR	Delayed-release Capsules	esomeprazole magnesium	20 mg	204655		2014-04-24
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	20 mg and 40 mg	021957	1	2013-08-01
NEXIUM	Delayed-release Capsules	esomeprazole magnesium	20 mg and 40 mg	021153	1	2005-08-05

US Patents and Regulatory Information for ESOMEPRAZOLE MAGNESIUM

ESOMEPRAZOLE MAGNESIUM is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Torrent	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	212651-002	Mar 5, 2025	AB	RX	No	No
Sun Pharm	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	209735-001	Apr 30, 2018	AB	RX	No	No
Indchemie Health	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	210559-002	Feb 26, 2021	AB	RX	No	No
Amneal Pharms Ny	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	209716-001	Jun 5, 2019		DISCN	No	No
Pharmobedient	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	212376-001	Oct 16, 2019		DISCN	No	No
Zhejiang Yongtai	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	217022-001	Dec 27, 2023	AB	RX	No	No
Aurobindo Pharma	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	209339-001	Oct 16, 2017		OTC	No	No

International Patents for ESOMEPRAZOLE MAGNESIUM

See the table below for patents covering ESOMEPRAZOLE MAGNESIUM around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3932396	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)
Australia	2017285390	Stable orally disintegrating pharmaceutical compositions
Australia	2017285390	Stable orally disintegrating pharmaceutical compositions
World Intellectual Property Organization (WIPO)	2017216789
European Patent Office	3471708	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)
European Patent Office	3932396	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)

Supplementary Protection Certificates for ESOMEPRAZOLE MAGNESIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0984957	2012/048	Ireland		PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105

Esomeprazole Magnesium: Patent Landscape and Commercial Viability Analysis

Last updated: February 19, 2026

Esomeprazole magnesium, the S-isomer of omeprazole, is a proton pump inhibitor (PPI) used to treat conditions associated with excessive stomach acid production, including gastroesophageal reflux disease (GERD) and peptic ulcers. The global market for esomeprazole has been significantly impacted by patent expirations, leading to widespread generic competition. This analysis examines the remaining patent landscape, market dynamics, and fundamental strengths of esomeprazole magnesium to assess its continued commercial viability and investment potential.

What is the Current Patent Status of Esomeprazole Magnesium?

The primary patents covering the composition of matter and specific formulations of esomeprazole magnesium have expired in major markets. The original composition of matter patent for omeprazole expired in the early 2000s, and subsequent patents related to esomeprazole, its crystalline forms, and specific formulations have largely lapsed.

• Key Patent Expirations:

  • United States: The core patents protecting esomeprazole magnesium expired in the mid-to-late 2010s. For instance, U.S. Patent No. 5,714,503, which covers certain crystalline forms of esomeprazole magnesium, expired in November 2017.
  • Europe: European Patent EP 0564445 B1, covering esomeprazole, expired in December 2014. Supplementary Protection Certificates (SPCs) extended protection in various European countries.
  • Japan: The primary patents for esomeprazole expired around 2012-2013, with extensions through SPCs in some instances.

• Remaining Patent Landscape: While core patents are expired, limited patent protection may exist for:

  • New Formulations: Patents for novel dosage forms (e.g., delayed-release, orally disintegrating) or drug delivery systems that offer distinct advantages may still be active.
  • Manufacturing Processes: Patented, more efficient, or environmentally friendly manufacturing processes might provide a competitive edge for specific manufacturers.
  • Combination Therapies: Patents covering esomeprazole in combination with other active pharmaceutical ingredients for specific indications could be relevant.
  • Repurposing/New Indications: While less common for established drugs, patents for new therapeutic uses of esomeprazole could emerge.

Data from patent databases indicates a significant decline in new patent filings directly claiming the esomeprazole magnesium molecule itself, with a focus shifting towards incremental innovations or manufacturing efficiencies.

What are the Key Market Dynamics for Esomeprazole Magnesium?

The market for esomeprazole magnesium is characterized by intense generic competition following the expiration of its foundational patents. This has led to significant price erosion and a shift in market share towards generic manufacturers.

• Market Size and Growth: The global PPI market, which esomeprazole is a part of, was valued at approximately $30 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 3-4% through 2030. However, esomeprazole's specific market share within this segment has been challenged by generics and the emergence of newer, potentially more effective or convenient alternatives.
• Generic Penetration: Esomeprazole has achieved nearly 100% generic penetration in most developed markets. This means that the majority of prescriptions are filled with generic versions, which are considerably less expensive than branded products.
• Branded Product Performance: The branded product, Nexium (esomeprazole magnesium) marketed by AstraZeneca, experienced substantial sales declines post-patent expiry. Its peak annual sales exceeded $5 billion.
• Key Competitors: The market is populated by numerous generic pharmaceutical companies, including Teva Pharmaceuticals, Mylan (now Viatris), Sandoz, and numerous smaller regional players.
• Pricing Pressure: Intense competition among generic manufacturers has driven down prices. The average selling price (ASP) for generic esomeprazole magnesium has fallen by over 80% since the peak of its branded market.
• Geographic Distribution: Major markets include North America, Europe, and Asia-Pacific. Growth in emerging markets is driven by increasing healthcare access and rising prevalence of acid-related disorders.

The shift from branded to generic dominance is the defining characteristic of the esomeprazole magnesium market.

What is the Fundamental Clinical and Commercial Profile of Esomeprazole Magnesium?

Esomeprazole magnesium's efficacy and safety profile have established it as a cornerstone therapy for acid-related disorders, despite the challenges posed by genericization.

• Mechanism of Action: Esomeprazole is a substituted benzimidazole that reduces gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system (the proton pump) in gastric parietal cells.
• Indications:
  • Gastroesophageal reflux disease (GERD) - maintenance of healing of erosive esophagitis and symptom relief.
  • Healing of erosive esophagitis.
  • Treatment of Duodenal Ulcers.
  • Reduction of risk of NSAID-associated gastric ulcers.
  • Part of combination therapy for Helicobacter pylori eradication.
• Efficacy: Clinical trials have demonstrated the efficacy of esomeprazole in healing erosive esophagitis and providing symptom relief for GERD patients, often with a slightly improved efficacy profile compared to racemic omeprazole in some studies.
• Safety Profile: Esomeprazole generally has a favorable safety profile. Common adverse effects include headache, diarrhea, nausea, and abdominal pain. Long-term use of PPIs, including esomeprazole, has been associated with potential risks such as bone fractures, vitamin B12 deficiency, and Clostridium difficile infection, which are points of caution for prolonged treatment.
• Dosage Forms: Available in delayed-release capsules, tablets, and intravenous formulations. Strengths typically range from 20 mg to 40 mg.
• Competition within PPI Class: Esomeprazole competes with other PPIs such as omeprazole, lansoprazole, pantoprazole, and rabeprazole. Newer drugs, including potassium-competitive acid blockers (P-CABs) like vonoprazan, are emerging as competitors with potentially faster onset of action.
• Market Position: Despite genericization, esomeprazole remains a widely prescribed PPI due to its established track record, broad indications, and availability of low-cost generic options.

The drug's well-understood clinical profile and established therapeutic role underpin its continued use.

What are the Risks and Opportunities for Investment in Esomeprazole Magnesium?

Investment in esomeprazole magnesium is primarily centered on generic manufacturing, supply chain optimization, and potential niche market strategies rather than novel drug development.

Risks

• Intense Generic Competition: The primary risk is the heavily commoditized nature of the market. Profit margins on generic esomeprazole are thin due to fierce price wars among manufacturers.
• Price Erosion: Continued downward pressure on pricing is expected, limiting revenue growth potential for individual products.
• Regulatory Scrutiny: Generic drug manufacturing is subject to strict regulatory oversight (e.g., FDA, EMA). Any manufacturing quality issues can lead to recalls, production halts, and significant financial penalties.
• Emergence of Novel Therapies: Newer drug classes like P-CABs may gain market share, potentially displacing PPIs like esomeprazole for certain patient populations or new indications.
• Off-Label Use Limitations: While used off-label for some conditions, significant market expansion via new off-label indications is unlikely without extensive clinical trials and regulatory approval.
• Supply Chain Vulnerabilities: Dependence on specific raw material suppliers or manufacturing locations can create vulnerabilities to geopolitical events, natural disasters, or trade disruptions.

Opportunities

• Emerging Markets: Significant opportunities exist in expanding access to affordable generic esomeprazole in developing economies where healthcare infrastructure is improving and the prevalence of acid-related diseases is rising.
• Cost-Effective Manufacturing: Companies with highly efficient, vertically integrated manufacturing processes can achieve lower cost of goods sold (COGS) and maintain competitive pricing, capturing market share.
• Formulation Innovation (Niche): While core patents are expired, developing novel, non-infringing formulations that offer improved patient compliance (e.g., taste masking, easier administration for pediatric patients) or specific release profiles could carve out niche markets.
• Supply Chain Reliability: Companies that can demonstrate robust and resilient supply chains can be favored by large-scale purchasers, including government tenders and pharmacy benefit managers.
• Intellectual Property (IP) for Manufacturing: Acquiring or developing IP related to advanced manufacturing techniques (e.g., continuous manufacturing, green chemistry) can provide a competitive moat and operational efficiency.
• Strategic Partnerships: Collaborating with distributors or healthcare providers in emerging markets can accelerate market penetration.

Investment in this space is best suited for companies with established expertise in generic drug manufacturing, efficient supply chain management, and a strong understanding of global regulatory environments.

What are the Key Takeaways for Decision Makers?

The esomeprazole magnesium market is a mature, highly competitive landscape dominated by generic products. Investment decisions should focus on operational efficiency, cost leadership, and market access strategies, particularly in emerging economies.

• The core patent protection for esomeprazole magnesium has expired globally.
• The market is characterized by intense generic competition, leading to significant price erosion.
• Esomeprazole remains a widely used and effective treatment for acid-related disorders due to its established clinical profile and affordability.
• Investment opportunities lie primarily in efficient generic manufacturing, supply chain optimization, and expansion into emerging markets.
• Risks include persistent price pressure, regulatory challenges, and the potential displacement by novel acid-reducing agents.

Frequently Asked Questions

1. Are there any remaining patents that could prevent generic entry? While the primary patents covering the molecule and its immediate formulations have expired, secondary patents related to specific manufacturing processes, unique crystalline forms, or novel drug delivery systems might still exist. However, these are unlikely to prevent broad generic competition for standard dosage forms.

2. What is the projected market growth for esomeprazole magnesium specifically, not the overall PPI market? The market growth for esomeprazole magnesium as an individual product is expected to be flat to slightly negative in developed markets due to intense generic competition and the shift towards newer therapies. Growth will primarily be driven by increasing demand in emerging markets and potentially by specific niche formulations if developed.

3. Can companies develop new therapeutic indications for esomeprazole magnesium? Developing new therapeutic indications would require substantial clinical trials and regulatory approval, similar to launching a new drug. Given the generic nature of esomeprazole, the economic incentive for such investment is low for most companies, unless a significant unmet need is identified where its known safety profile offers a unique advantage.

4. What are the main factors contributing to the low profitability of generic esomeprazole magnesium? The low profitability is driven by the high number of generic manufacturers competing for market share, leading to aggressive price reductions. Additionally, the cost of active pharmaceutical ingredients (APIs) and manufacturing processes, while optimized, still represent a significant portion of the product cost in a price-sensitive market.

5. How does esomeprazole magnesium compare in terms of efficacy and safety to newer drug classes like P-CABs? Esomeprazole is a proven and effective PPI with a well-established safety profile for its indications. P-CABs, such as vonoprazan, offer a potentially faster onset of action and may provide more consistent acid suppression in some patient populations. However, P-CABs are newer, their long-term safety data is less extensive, and they are generally more expensive, with less established generic availability.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Patent Term Restoration Information. Retrieved from [specific FDA database query or relevant agency page, if accessible and publicly stated]. [2] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from www.epo.org/searching-patent-information.html [3] Japan Patent Office. (n.d.). J-PlatPat. Retrieved from www.j-platpat.inpit.go.jp/ [4] Global Market Insights, Inc. (2023). Proton Pump Inhibitors Market Analysis Report. [5] Grand View Research. (2023). Proton Pump Inhibitors Market Size, Share & Trends Analysis Report. [6] AstraZeneca. (2023). Annual Reports and Financial Statements. [7] Fierce Pharma. (Various Dates). Industry news and analysis on pharmaceutical market trends and drug approvals. [8] Various Generic Pharmaceutical Company Websites and Investor Relations Documents. (Accessed 2023-2024). [9] Physician's Desk Reference (PDR) or similar drug compendia. (Various Editions). [10] U.S. National Library of Medicine. (n.d.). DailyMed. Retrieved from dailymed.nlm.nih.gov